All In Biotech

Drug Trial Radar · NCT04036435

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,466

Actual

Start

Aug 12, 2019

Primary completion

Jul 21, 2026

Study completion Jul 21, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have been previously enrolled in an applicable Phase 3 psoriasis study. In addition, the study includes a vaccine cohort to evaluate whether deucravacitinib impacts the humoral immune response to 2 non-live vaccines, the Pneumovax 23 vaccine (pneumococcus), a T-cell independent vaccine, and the Boostrix vaccine (tetanus toxoid), a T-cell dependent vaccine. Additionally, this vaccine cohort assesses the safety of administering these vaccines to subjects with psoriasis receiving deucravacitinib compared to those receiving a placebo.

Conditions

  • Psoriasis

Interventions

  • BMS-986165Drug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: Up to 244 weeks
  2. Incidence of Serious Adverse Events (SAEs)Time frame: Up to 244 weeks
  3. Proportion of participants achieving a satisfactory humoral response: pneumococcusTime frame: At Week 4 post vaccination
  4. Proportion of participants achieving a satisfactory humoral response: tetanus titersTime frame: At Week 4 post vaccination

Locations

302 sites in 20 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center

    Birmingham, Alabama

  • Local Institution - 0278

    Birmingham, Alabama

  • Alliance Dermatology and Mohs Center - Phoenix

    Phoenix, Arizona

  • Arizona Research Center

    Phoenix, Arizona

  • Synexus - Orange Grove Family Practice

    Tucson, Arizona

  • Johnson Dermatology

    Fort Smith, Arkansas

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Northwest Arkansas Clinical Trials Center, PLLC

    Rogers, Arkansas

  • Local Institution - 0046

    Fountain Valley, California

  • Local Institution - 0206

    Fresno, California

  • Local Institution - 0017

    Irvine, California

  • Interspond - Long Beach Clinical Trials

    Long Beach, California

  • Dermatology Research Associates - Los Angeles

    Los Angeles, California

  • Local Institution - 0236

    Los Angeles, California

  • University of California San Diego Health Systems

    San Diego, California

  • Therapeutics Clinical Research

    San Diego, California

  • University Dermatology Group

    San Diego, California

  • Local Institution - 0094

    San Luis Obispo, California

  • Clinical Science Institute

    Santa Monica, California

  • NorthBay Clinical Research

    Santa Rosa, California

  • Synexus - Santa Rosa

    Santa Rosa, California

  • Local Institution - 0042

    Sherman Oaks, California

  • Care Access Research - Walnut Creek

    Walnut Creek, California

  • New England Research Associates

    Bridgeport, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • Local Institution - 0170

    Boca Raton, Florida

  • ERN - Accel Research Sites

    DeLand, Florida

  • Indago Research and Health Center

    Hialeah, Florida

  • LCC Medical Research

    Miami, Florida

  • International Dermatology Research

    Miami, Florida

  • Well Pharma Medical Research

    Miami, Florida

  • Local Institution - 0216

    Miami, Florida

  • Interspond - Savin Medical Group

    Miami Lakes, Florida

  • Local Institution - 0007

    Miami Lakes, Florida

  • Local Institution - 0198

    Port Orange, Florida

  • Local Institution - 0233

    Tampa, Florida

  • Local Institution - 0008

    Tampa, Florida

  • Local Institution - 0013

    Marietta, Georgia

  • Local Institution - 0235

    Sandy Springs, Georgia

  • Treasure Valley Dermatology & Skin Cancer Center

    Meridian, Idaho

Showing 40 of 302 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.